SGMO : Summary for Sangamo BioSciences, Inc. - Yahoo Finance

U.S. Markets closed

Sangamo BioSciences, Inc. (SGMO)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
3.20+0.50 (+18.52%)
At close: 4:00 PM EST
People also watch:
SGENALNYPGNXZIOPHALO
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close2.70
Open2.70
Bid3.05 x 100
Ask3.25 x 100
Day's Range2.70 - 3.35
52 Week Range2.65 - 9.83
Volume1,494,964
Avg. Volume923,942
Market Cap226M
Beta2.94
PE Ratio (TTM)-2.96
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Capital Cube15 hours ago

    ETFs with exposure to Sangamo BioSciences, Inc. : December 9, 2016

    Categories: ETFs Yahoo Finance Click here to see latest analysis ETFs with exposure to Sangamo BioSciences, Inc. Here are 5 ETFs with the largest exposure to SGMO-US. Comparing the performance and risk of Sangamo BioSciences, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • PR Newswire4 days ago

    Sangamo BioSciences Presents Hemophilia A Program Data At The 2016 American Society Of Hematology Meeting

    RICHMOND, Calif., Dec. 5, 2016 /PRNewswire/ -- Sangamo BioSciences, Inc. (SGMO), the leader in therapeutic genome editing, announced the presentation of preclinical and manufacturing data that support SB-525, its gene therapy program for hemophilia A, at the 58th Annual Meeting of the American Society of Hematology (ASH) being held in San Diego, CA, from December 3-6, 2016. "We have developed an improved gene therapy vector for treatment of hemophilia A which we believe is highly competitive, and we remain on track to file an Investigational New Drug (IND) application for our clinical program by the end of 2016," said Sandy Macrae, M.B., Ch.B., Ph.D., Sangamo's president and chief executive officer.  "This program illustrates Sangamo's drug development capabilities beyond our ZFP platform.

  • What Smart Money Thinks about EZCORP Inc (EZPW)?
    Insider Monkey5 days ago

    What Smart Money Thinks about EZCORP Inc (EZPW)?

    Reputable billionaire investors such as Nelson Peltz and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required to invest in a hedge fund and most successful hedge funds won’t accept your savings unless you commit at least $5 million) by pinpointing winning small-cap […]